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moted by the combined action of long-term chronic inflam-
mation and targeted perturbations of cellular key pathways 
involved in metabolic homeostasis as well as cell cycle con-
trol.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Persistent infection with the hepatitis C virus (HCV) 
is a major global health problem. Around 170 million 
people are infected with this virus, corresponding to 
  3% of the world’s population. These people are at high 
risk of developing serious liver damage;   20% develop 
liver cirrhosis within 20–30 years after infection and peo-
ple with HCV-associated cirrhosis develop hepatocellular 
carcinoma (HCC) in 1–6% of cases per year. Although for 
many types of cancer the incidence rates are stable or 
even declining, in liver cancer they are rising. In fact, 
HCC, which accounts for 70–85% of liver cancers  [1] , is 
the most frequently diagnosed cancer worldwide in men 
and the second most frequent cause of cancer death. In 
women, it is the seventh most commonly diagnosed can-
cer and the sixth leading cause of cancer death  [2] . Re-
markably, HCV infection accounts for a large proportion 
of these liver cancers. The prognosis of patients with 
HCC is poor and the 1-year survival remains less than 
50% in the USA  [3] .
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 Abstract 
 Persistent infection with the hepatitis C virus (HCV) is a major 
global health problem. Around 2–3% of the world’s popula-
tion are chronically infected, and infected individuals are at 
high risk of developing steatosis, fibrosis, and liver cirrhosis. 
The latter is a major predisposing factor for the development 
of hepatocellular carcinoma (HCC). It is generally accepted 
that an inflammatory response triggered by persistent HCV 
infection leads to increased cell proliferation and fibrogen-
esis that in turn promotes cirrhosis and ultimately HCC de-
velopment. This indirect mechanism of tumor induction 
would explain the long incubation period from primary HCV 
infection to HCC and the requirement for additional cofac-
tors such as toxins or drugs (most notably alcohol), meta-
bolic liver diseases, steatosis, nonalcoholic liver disease, or 
diabetes. With the advent of adequate cell culture systems 
for HCV it is, however, becoming increasingly clear that the 
virus also contributes directly to HCC formation. Examples 
are the continuous induction of stress response or the mas-
sive accumulation of intracellular lipids. Moreover, viral pro-
teins can bind to and sequester cell cycle control factors
such as the retinoblastoma protein or the tumor suppressor 
DDX3. Thus, HCV-associated liver cancer is most likely pro-
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 In the absence of adequate in vivo/animal models, 
analyses of HCV-induced pathogenesis are difficult. 
Thus, most studies are based on the use of engineered in 
vitro culture systems that are inherently prone to arti-
facts caused, for example, by ectopic overexpression of 
single HCV proteins. Moreover, in many studies heter-
ologous cell systems of nonhepatic or nonhuman origin 
have been used. Some of these limitations have been over-
come with the implementation of more authentic cell cul-
ture systems recapitulating the HCV life cycle in parts 
(e.g. the replicon system) or in total [reviewed in  4 ]. The 
latter is based primarily on a particular HCV isolate, des-
ignated JFH1 (an acronym derived from Japanese fulmi-
nant hepatitis), that replicates to exceptionally high levels 
in the human hepatoma cell line Huh7. Importantly, 
HCV particles produced in these cells are infectious in 
vivo (i.e. immunodeficient transgenic mice with human 
liver xenografts) and particles isolated from these in vivo 
samples are infectious for Huh7 cells  [5] . While these are 
important achievements, the primary restriction to Huh7 
human hepatoma cells is a serious limitation.
 Chronic inflammation induced by viral infection ap-
pears to be a major predisposing condition for liver can-
cer. In the case of hepatitis C it is assumed that a persis-
tently activated immune reaction targeting infected liver 
cells leads to increased cell proliferation and fibrogenesis, 
thus enhancing cirrhosis and HCC development  [6, 7] . 
This indirect mechanism of tumor induction by HCV in-
fection could explain why tumors most often develop 
only 10–30 years after primary infection and require ad-
ditional risk factors such as alcohol consumption, meta-
bolic liver diseases, or diabetes  [6] . Nevertheless, there is 
increasing evidence that HCV itself, or specific viral pro-
teins, contribute directly to HCC formation. In the fol-
lowing sections, we will focus on some of the possible 
direct contributions of HCV to the development of HCC 
and the molecular mechanisms underlying this process.
 HCV Replication Cycle 
 Understanding the molecular mechanisms underly-
ing the development of HCV-associated HCC requires 
detailed knowledge of the viral replication cycle and the 
interaction of HCV with its host cell. With the advent
of robust culture models and molecular biological ap-
proaches, the principles by which HCV replicates have 
been unraveled ( fig. 1 )  [8–12] . The virus enters the host 
cell, which is primarily the hepatocyte, via receptor-me-
diated endocytosis. It is achieved by interactions between 
the virus particle and numerous host cell molecules pre-
sumably in a consecutive manner. Virus particles are 
probably trapped on the surface of the hepatocyte by in-
teraction with glycosaminoglycans and low-density li-
poprotein (LDL) receptors that likely interact with the 
lipoprotein moiety of the HCV particle. Subsequent in-
ter actions involve CD81, scavenger receptor B1 (SR-B1), 
claudin-1 and occludin. The efficiency of entry is en-
hanced by direct or indirect interaction between HCV 
and the Niemann-Pick C1-like 1 (NPC1L1) cholesterol 
uptake receptor and the epidermal growth factor receptor 
(EGFR), respectively  [11, 13, 14] . Upon HCV entry, the 
viral genome is released into the cytoplasm. This plus-
strand RNA has a length of   9,600 nucleotides and con-
tains one long open reading frame that is flanked by two 
terminal nontranslated regions that form higher-order 
RNA structures. The 5  nontranslated region contains an 
internal ribosome entry site (IRES) mediating the trans-
lation of the RNA genome and giving rise to a polyprotein 
that is cleaved by host proteases and two viral proteases 
into 10 different products. The N-terminal region of the 
polyprotein is composed of the structural protein core, 
envelope glycoprotein 1 (E1) and E2. These proteins are 
the major building blocks of the virus particle. The fol-
lowing two auxiliary proteins are required for the assem-
bly of infectious HCV particles, but it is unclear whether 
they are also part of the virus particle: p7, a small hydro-
phobic protein that may act as an ion channel, and non-
structural protein 2 (NS2), that appears to contribute to 
some step of virus formation. The remainder of the NS 
proteins is sufficient for replication of the viral genome 
 [15] . NS3 contains in its N-terminal domain a serine-type 
protease that is tightly associated with and activated by 
NS4A. The C-terminal NS3 domain contains NTPase/
helicase activity. NS4B is a protein inducing the forma-
tion of the so-called membranous web that probably har-
bors the replicase complex. NS5A is an important regula-
tor of RNA replication and virus assembly and NS5B is 
the RNA-dependent RNA polymerase (RdRp), the key 
enzyme of viral genome amplification.
 HCV RNA is amplified via a minus-strand RNA tem-
plate and the newly synthesized plus-strand RNA is ei-
ther used for RNA translation and replication or pack-
aged into progeny HCV particles. Viral replication oc-
curs exclusively in the cytoplasm and leads to massive 
rearrangements of intracellular membranes mostly in-
duced by NS4B. The assembly and release process of 
progeny virus is closely associated with the lipid metabo-
lism of the cell [reviewed in  9 ]. As a result, infectious 
HCV particles have a unique composition and contain, in 
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addition to E1 and E2, components of the ‘very LDL’ 
(VLDL) system, most notably apolipoprotein E (ApoE). 
Moreover, HCV particles have a unique lipid composition 
that is very distinct from all other viruses analyzed so far 
and from the human liver cells in which the virus repli-
cates.
 Pathogenesis of Chronic Hepatitis C: Implications 
for HCC Development 
 Since HCV replicates exclusively in the cytoplasm 
without integration of the viral genome into the host cell 
chromosome, persistence can only be achieved by con-
tinuous viral replication. HCV also triggers an immune 
response that is, however, inefficient; it does not clear the 
virus, but sustains a chronic inflammation. This is exem-
plified, among other things, by: (i) the correlation be-
tween the strength of the immune response and clinical 
manifestation of hepatitis C, (ii) the lack of correlation 
between the level of viremia and the course of diseases, 
and (iii) the observation that patients treated with ribavi-
rin monotherapy normalize liver histology even though 
viremia is not affected. Thus, an inefficient immune re-
sponse unable to eradicate HCV appears to sustain a 
chronic inflammation ( fig. 2 ). This in turn likely increas-
es cell turnover and thus the chance for manifestation of 
alterations affecting the control of cell growth. Such al-
terations are promoted by various conditions including 
risk factors of DNA damage (e.g. aflatoxins), cirrhosis 
(e.g. alcohol consumption), or steatosis (e.g. diabetes) [for 
detailed reviews, see  16–19 ]. Apart from these indirect 
and host-determined effects, it is becoming increasingly 
clear that the virus itself also contributes to tumor pro-
gression ( fig. 2 ,  table 1 ). For instance, it has been shown 
that the core protein binds to and sequesters the tumor 
suppressor protein DDX3  [20] . Along the same lines, it 
has been convincingly demonstrated that nonstructural 
 Fig. 1. Schematic of the HCV replication 
cycle. Numbers refer to the individual 
steps of the cycle. For details, see text.
MW = Membranous web. 
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protein 5B (NS5B), which is the RNA-dependent RNA 
polymerase, binds to and sequesters the retinoblastoma 
protein (Rb)  [21] . Although experimental proof so far is 
missing, it is tempting to speculate that DDX3 or Rb se-
questration by core protein or NS5B, respectively, might 
affect cell cycle control and thus contribute rather direct-
ly to tumor progression.
 Another viral protein that received much attention in 
this context is NS5A. It is a highly phosphorylated protein 
required for HCV RNA ( table  1 ) replication and virus 
production. NS5A is composed of an amino-terminal 
amphipathic   -helix that tethers the protein to intracel-
lular membranes, an RNA-binding domain 1 that forms 
homodimers, and two natively unfolded protein domains 
that can form multiple complexes with host cell proteins 
 [22] . It is this structural property of domains 2 and 3 that 
explains why so many NS5A-interacting host cell factors 
have been identified, in most cases, in rather artificial 
systems such as the yeast-two-hybrid system. Moreover, 
in several cases artificially truncated NS5A variants have 
been used that display biochemical properties not found 
with the authentic full-length proteins. Thus, even though 
some of the cellular NS5A interactants have been con-
firmed in more authentic cell-based replication systems, 
in most instances this is not the case and, therefore, the 
physiological relevance of NS5A for alterations of cellular 
homeostasis and the contribution of this protein to tumor 
formation remain to be determined.
 With the advent of authentic cell culture systems it is 
becoming clear that, apart from individual viral proteins, 
HCV infection and replication per se induces numerous 
cellular and metabolic alterations that likely contribute to 
tumor progression. Examples are the induction of oxida-
tive and ER stress, the enhanced production and secre-
tion of TGF-  , and the enhanced accumulation of lipids. 
Two of these alterations will be described below. The 
reader interested in more details is referred to excellent 
recent reviews  [16, 17, 23, 24] .
 Induction of Stress Response and Impact on Viral 
Persistence and Cell Survival 
 It is known that HCV infection triggers various stress 
responses [reviewed in  23, 25 ]. Recently, we were able to 
show that in cells treated with interferon (IFN)-  , HCV 
potently induces the highly dynamic assembly and disas-
sembly of cytoplasmic stress granules (SGs). These struc-
tures represent sites of polyA+ mRNA sorting and stor-
age. Unlike P-bodies, mRNAs in SGs are not degraded 
but rather stabilized (‘stored’) within this compartment 
 [26] . By employing live-cell imaging techniques we char-
acterized the mechanism by which HCV triggers SG for-
mation and dynamics and found that SG assembly and 
disassembly correlates with phases of stalled and active 
RNA translation, respectively. Importantly, SG forma-
tion correlates with delayed cell division and prolonged 
cell survival, suggesting that oscillation of HCV-induced 
stress response contributes to persistence by suppressing 
cell death  [48] . While it is likely that this strategy facili-
 Fig. 2. Schematic representation of the dif-
ferent conditions promoting the develop-
ment of HCV-associated liver cancer. Pro-
liferation of hepatocytes is affected by 
chronic inflammation. Control of the cell 
cycle (black circle) is affected by multiple 
external cues that depend either on the 
host (grey box) or viral infection (black 
box). In addition, two HCV proteins (core 
and NS5B) might affect the cell cycle di-
rectly by sequestration of cell cycle control 
factors. For further details, see text. 
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tates persistent infection by HCV, it remains to be deter-
mined whether this indirect mechanism of suppression 
of cell death plays a role in HCV-associated liver cancer.
 Association of HCV Infection with Steatosis and 
Development of Liver Cancer 
 One of the hallmarks of HCV infection is the induction 
of steatosis, which is a condition that contributes to tumor 
development. In fact, using the JFH1-based cell culture 
system we observed a   3-fold higher amount of lipids in 
HCV-infected Huh7 cells versus noninfected control cells. 
This elevated lipid synthesis might be brought about, 
among other things, by the induction of a massive ER 
stress response that in turn could activate the SREBP (ste-
rol regulatory element-binding protein) pathway. SREBP 
is an ER-resident inactive transcription factor that under 
conditions of ER stress is transported to the Golgi. There 
SREBP is cleaved by proteases liberating a cytosolic pro-
tein fragment that is transported into the nucleus and that 
activates transcription of genes required for the synthesis 
of cholesterol and for fatty acid homeostasis  [27] . 
 Why does HCV cause such profound alterations of in-
tracellular lipid pools? On one hand, enhanced lipid syn-
thesis appears to promote viral RNA replication and
virus production; on the other hand, it might reflect a
‘collateral damage’ caused by viral exploitation of key en-
zymes involved in lipid synthesis and intracellular lipid 
storage. With respect to the first scenario, one has to keep 
in mind that HCV replication occurs on ER-derived 
membranes. Thus, efficient assembly of viral replication 
complexes requires the rearrangement of existing mem-
branes but probably also their novel synthesis. Early stud-
ies by Egger et al.  [28] described that profound membrane 
alterations are mainly induced by NS4B. Overexpression 
of this highly hydrophobic protein induced the formation 
of single membrane vesicles forming clusters and appear-
ing as a ‘membranous web’. Subsequent studies suggest 
that this web is the site of HCV RNA replication  [29] . Us-
ing electron microscopy and tomography in combination 
with 3D reconstructions, we observed in HCV-infected 
human hepatoma cells numerous membrane alterations 
[Romero-Brey et al., unpubl. data]. Most prominent were 
double membrane vesicles that were most abundant and 
that might be sites of RNA replication. In addition, at late 
stages after infection we detected multi-membrane vesi-
cles that probably reflect cellular stress-induced reactions 
including autophagic responses.
Table 1. H CV proteins and their possible contribution to pathogenicity and liver cancer development
HCV protein Role in the replication cycle Possible role in pathogenicity
Core Nucleocapsid Insulin resistance/steatosis/oxidative stress
Interference (direct or indirect) with p53, p73, and pRb
Interference with host cell signaling pathways 
(NF-B, Raf1/MAPK, Wnt/-catenin)
Interference with TGF- signaling
Transcriptional activation of cellular genes
NS2 Protease/assembly Modulation of apoptosis
NS3 Protease/helicase Interference with innate immune response
Interference with NF-B
Interference with p53
NS4B Induction of ER stress
NS5A Interference with protein ubiquitination 
Inhibition of PKR activity
Induction of oxidative stress
Modulation of transcription of cellular genes
Activation of signaling pathways (STAT-3, NF-B, etc.)
Activation of phosphatidyl inositol-4-kinase
Accumulation of -catenin by indirect mechanisms
NS5B Sequestration of Rb
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 The interaction of the HCV core protein with lipid 
droplets (LDs), which are intracellular storage organelles 
for neutral lipids (mainly triacylglycerol and/or choles-
terol esters) [reviewed in  30–32 ], is another example il-
lustrating how this virus alters lipid homeostasis of the 
cell. We and others could demonstrate that assembly of 
HCV particles is tightly linked to LDs, which are sites 
where structural and nonstructural proteins accumulate 
during assembly  [12, 33–35] . Importantly, HCV core pro-
tein impacts lipid metabolism in several ways: (i) by inhi-
bition of LD mobility, (ii) by decreasing the lipid turnover 
in core-coated LDs, (iii) by inhibition of MTP (micro-
somal triglyceride transfer protein), (iv) by inhibition of 
VLDL secretion, and (v) by inhibition of DGAT-1 (dia-
cylglycerol acyltransferase 1)  [36–41] . These alterations 
appear to play important roles in pathogenesis. For in-
stance, in an elegant recent study it was shown that mice 
lacking DGAT-1 are protected from HCV core-induced 
lipid accumulation  [42] . This could be ascribed to a de-
crease in lipid turnover in core-coated LDs. Thus, HCV 
promotes steatosis both by decreasing lipid mobilization 
and by reducing lipid release via interference with VLDL 
secretion.
 In vivo Studies on the Role of HCV in Promoting 
Liver Cancer 
 Studies of the role of HCV in promoting liver cancer 
development are limited by the lack of an HCV-permis-
sive and immunocompetent animal model. Apart from 
humans, only chimpanzees are susceptible to HCV infec-
tions, but owing to ethical concerns and high costs their 
use is virtually impossible. To overcome these lim itations, 
two alternative attempts are pursued: first, the generation 
of transgenic animals expressing HCV pro tein(s), and 
second, the development of an immunocompetent and 
HCV-permissive mouse model. With respect to the first 
approach, most studies have focused on transgenic mice 
expressing constructs containing the core protein or 
NS5A. It appears that, depending on the used mouse 
strain, expression construct, or experimental conditions, 
steatosis and occasionally HCC develop [reviewed in  16 ]. 
While these results support the notion that HCV proteins 
can promote tumor development, with one exception, 
only polyprotein fragments or isolated protein (core or 
NS5A) have been expressed and tumors have only been 
found in the C57BL/6 mouse background. Thus, the rel-
evance of these observations for infections in humans re-
mains to be determined.
 With respect to the second approach, in the last few 
years several transgenic mouse models have been estab-
lished that are, however, immunodeficient and rely on the 
transplantation of human liver xenografts  [43–45] . The 
first model, originally described by Kneteman and co-
workers used a upa/SCID mouse strain that expresses the 
toxic urokinase plasminogen activator (upa) selectively in 
the liver  [43] . Soon after birth, the upa transgene is ex-
pressed and a high proportion of mouse hepatocytes are 
destroyed. During this phase, animals can be rescued by 
transfer of primary human hepatocytes that migrate into 
the liver and form human liver cell ‘nests’ in an otherwise 
murine liver architecture. Engrafted human hepatocytes 
can be infected productively with HCV, but since these 
animals are immunodeficient to avoid graft rejection, 
this system is not useful for studies of HCV-associated 
carcinogenesis. An improvement of this mouse model 
was recently described by Washburn et al.  [46] . They gen-
erated AFC8-hu HSC/Hep mice by co-transplanting hu-
man CD34 + hematopoetic stem cells (HSC) and hepato-
cyte progenitors (Hep) into mice that were transgenic for 
caspase 8 that was expressed under control of the albu-
min receptor promoter (ACF8). Expression of caspase 8 
in liver cells is toxic, thus creating ‘space’ for transplanta-
tion of human liver cells. The authors could show that 
these AFC8-hu HSC/Hep mice supported HCV infection 
in the liver and mice developed an HCV-specific T cell 
response that was, however, very weak  [46] .
 More recently, Dorner et al.  [47] established a geneti-
cally humanized mouse model. By adenoviral transfer of 
the HCV entry factors CD81 and occludin into mouse 
liver cells, the animals became infectable but did not sup-
port HCV replication to a directly detectable level. To 
overcome this limitation, the authors made use of the 
 Rosa26-Fluc mouse strain that expresses an inactive lu-
ciferase reporter gene that can be activated upon expres-
sion of the CRE recombinase. Upon infection of these 
animals with an engineered HCV expressing this recom-
binase, a small but detectable fraction of inoculated liver 
cells started to fluoresce, indicating infection of the cells 
and expression of the (HCV-encoded) CRE recombinase. 
Although this mouse model is still very inefficient, for the 
first time HCV replication in an inoculated immuno-
competent transgenic mouse was detected. It is obvious 
that much more work will be required to improve this 
mouse model to a level that supports the complete HCV 
replication cycle, but only with the availability of such an 
immunocompetent in vivo system will it become possible 
to study the contribution of (persistent) HCV infection to 
the development of liver cancer.
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